CELYAD ONCOLOGY SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.326 EUR | -2.54% |
|
-6.32% | -16.41% |
| Apr. 04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Presentation Operator MessageOperator (Operator)Welcome to the Celyad Oncology Second Half 202...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.41% | 14.74M | |
| -1.82% | 41.36B | |
| +44.25% | 41.3B | |
| +2.56% | 39.61B | |
| -12.11% | 25.62B | |
| +3.09% | 24.09B | |
| -24.16% | 18.38B | |
| +22.12% | 11.85B | |
| -3.74% | 11.82B | |
| +7.75% | 11.07B |
- Stock Market
- Equities
- CYAD Stock
- News Celyad Oncology SA
- Transcript : Celyad Oncology SA, 2021 Earnings Call, Mar 25, 2022
